Management of Bleeding
{"Image DocumentName": "Management of Bleeding", "Image ImageDescription": "Mild bleeding. Patient with bleeding on dabigatran therapy. Life-threatening bleeding. Moderate-Severe bleeding. Delay next dose or discontinue treatment as appropriate. Discontinue dabigatran. Consideration of rFVIIa or PCC  Charcoal filtration  Symptomatic treatment. Mechanical compression. Surgical intervention. Fluid replacement and hemodynamic support. Blood product transfusion. Oral charcoal application  (if dabigatran taken < 2 hrs prior) Hemodialysis.   Based on limited non-clinical data only, there is no experience in volunteers or patients rFVIIa: recombinant activated factor VII; PCC: prothrombin complex concentrates. van Ryn J et al. Thromb Haemost 2010;103:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}